India first Zika vaccine infographic: Phase I trial, adults 18-50, 3:1 randomisation

India’s first Zika vaccine is a step closer to human testing: the CDSCO Subject Expert Committee on vaccines has recommended that Indian Immunologicals Limited (IIL), through its Human Biologicals Institute division, be allowed to run a Phase I trial of its recombinant live attenuated Zika vaccine in healthy adults aged 18 to 50, Business Standard reported on 15 November 2026. The study, developed with Australia’s Griffith University and funded by ICMR, still needs final regulatory permission before dosing begins.

Key takeaways on India’s first Zika vaccine

  • The CDSCO expert panel recommended the Phase I protocol at its November meeting, about two months after IIL first submitted it in September 2026.
  • The candidate is a freeze-dried recombinant live attenuated vaccine, co-developed with Griffith University.
  • The trial is planned as randomised, double-blind and placebo-controlled, with a 3:1 vaccine-to-placebo ratio, at ICMR network sites.
  • ICMR will fund Phase I costs, including trial conduct, investigations and monitoring.
  • No Zika vaccine has yet been licensed anywhere in the world, so even early data would be closely watched.

From panel queries to recommendation

The approval path was not instant. When the Subject Expert Committee (SEC) first reviewed the proposal on 23 September 2026, it sent IIL back with a list of questions: the rationale for the chosen dose, statistical justification for the sample size, the reasoning behind the 3:1 randomisation, how cohorts would be selected, and full non-clinical study reports rather than the summary it had received. After the company supplied that information, the panel reconsidered and recommended the trial in November.

That sequence is a useful reminder of how India’s vaccine regulation now works. An SEC recommendation is advice to the Drugs Controller General of India; formal trial permission, ethics committee clearances at each site and trial registration still follow. Investors and public health watchers should therefore read this as a green light in principle rather than a start date.

Trial snapshot

ParameterDetail
SponsorIndian Immunologicals Ltd (Human Biologicals Institute)
PartnersGriffith University (technology); ICMR (funding, trial network)
Vaccine typeRecombinant live attenuated, freeze-dried
PhasePhase I, first in human
DesignRandomised, double-blind, placebo-controlled
Randomisation3:1 (vaccine : placebo), so 75% of volunteers get the vaccine
PopulationHealthy adults, 18 to 50 years
EndpointsSafety, reactogenicity, immunogenicity
Pre-clinical workAcute and repeat-dose toxicity; animal immunogenicity and challenge studies
Sample size / sitesNot disclosed; ICMR network sites

How a live attenuated Zika vaccine is meant to work

Live attenuated vaccines use a weakened form of a virus that can replicate just enough to train the immune system without causing disease. India already relies on this platform for measles, rubella and other routine immunisations, and it tends to produce strong, durable immunity from few doses. The trade-off is safety: live vaccines are generally avoided in pregnancy and in people with weakened immunity. That is a significant consideration for Zika, because the main harm of the virus is to the developing foetus, so the eventual target population and use strategy will matter as much as the immune response.

Phase I will not answer whether the vaccine prevents infection. Its job is to show the shot is safe, tolerable, and induces antibodies in healthy adults, so that dose-finding and larger efficacy or immunobridging studies can follow.

Why India needs a Zika vaccine

Zika is spread mainly by Aedes mosquitoes, the same vectors that carry dengue and chikungunya across Indian cities. India confirmed its first Zika cases in 2016 and has since seen sporadic, localised clusters in several states. According to the report, India has so far not recorded confirmed Zika-linked microcephaly or Guillain-Barré syndrome cases, but the risk to pregnant women during outbreaks is the reason the WHO treats Zika as a priority pathogen. A home-grown vaccine would also give India a ready tool for outbreak response rather than depending on imports that do not yet exist.

The project is part of a broader ICMR push to co-develop products with Indian manufacturers; see our report on the ICMR medical device development initiative. On the regulatory side, CDSCO is also tightening rules for anti-infectives, as covered in India’s draft rule treating antimicrobials as new drugs.

Market context

India is already the world’s largest vaccine supplier by volume, and new candidates like this one feed a fast-growing global market. Acumen Research and Consulting estimates the global vaccines market at USD 59.4 billion in 2023, projected to reach USD 115.3 billion by 2032 at a 7.8% CAGR, with Asia-Pacific the fastest-growing region. Treat these as indicative figures; a Zika vaccine would address a small, outbreak-driven slice of that market unless it wins a place in travel or routine immunisation programmes.

What we still do not know

  • The number of volunteers and the specific trial sites.
  • When the DCGI will grant formal permission and when the first participant will be dosed.
  • Dose levels being tested and whether one or two doses are planned.
  • How the vaccine would eventually be used given live vaccines are usually avoided in pregnancy.

FAQ

Is there a Zika vaccine available in India?

No. No Zika vaccine is licensed in India or elsewhere. IIL’s candidate has only been recommended for a Phase I safety trial.

Who is developing India’s first Zika vaccine?

Indian Immunologicals Limited, through its Human Biologicals Institute, with Griffith University in Australia and funding from ICMR.

When will the Zika vaccine trial start?

No start date has been announced. The trial needs formal DCGI permission and site approvals after the SEC recommendation.

How does Zika spread?

Mainly through bites from infected Aedes mosquitoes; it can also pass from mother to foetus and through sexual contact.

Sources: Business Standard (15 Nov 2026) reporting on CDSCO Subject Expert Committee deliberations; CDSCO. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated 21 November 2026.

More in Clinical Trials.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *